Table 4(A).
Synthesis and characterization of various types of chitosan-based nanoparticles in vitro and in vivo environments, reported in different studies
| Reference Properties |
48 | 5 | 27 | 24 | 7 | Present study |
|---|---|---|---|---|---|---|
| Name | NQC-AmpB | HePC-AmB-CNLCs | Cs-PF-AmB-M | Chitosan-coated AmB-loaded SLNs | MTC AmB | AK |
| Nanoparticle size (nm) | 135 | – | – | 148 | – | 102 |
| Nanodrugs size (nm) | 155 | 150 | 156 | 166 | 362 | 112 |
| Synthesis method | Ionic gelation | Emulsification and homogenization | Ionic gelation | Emulsification and solvent evaporation | Ionic gelation | Phase separation |
| Drug loading efficiency (%) and methods used for confirmation | 81%; DLS, SEM, TEM | 80%; DLS, TEM | 63%; DLS | 82%; SEM, DLS | 73%; FTIR, SEM | 90%; DLS, SEM, TEM, AFM, HNMR, FTIR |
| Pattern of drug release | Controlled release | Controlled release | Controlled release | Biphasic | Controlled release | Controlled release |
| Cellular uptake (%) | 32% | 55% | 22% | 34% | 45% | 98.6% |
| In vitro viability (%) (MTT) | 50% at 9 µg/mL | 58% at 10 µg/mL | 72% at 20 µg/mL | 49% at 20 µg/mL | 34% at 57 µg/mL | 100% at 20 µg/mL |
| Promastigote killing (%) | 50% at 1 µg/mL | – | – | – | – | 82% at 20 µg/mL |
| Amastigote inhibition (%) | 61% | 68% | 50% | 50% | 61% | 78% |
| Leishmania species | Amazonensis | Donovani | Donovani | Donovani | Donovani | Major |